DNA microarray technology has empowered biomedical research through the ability to accomplish whole genome analysis in a single experiment. Applications of this technology include: high throughput genotyping on oligonucleotide chips to home in on multi-factorial disease loci, detection of recurrent rearrangement of the gene expression level through expression arrays as well as determining the effect of therapeutic agents on gene expression in tissues derived from animal models for human cancer. The ability to leverage tremendous amounts of genomic data into an all encompassing, comprehensive understanding of basic cell biology and physiology has tremendous implications for the future of biomedical research. The DNA Microarray Resource with afford RPCI with the technology to revolutionize its research program, moving tem forward into functional genomics by allowing massive parallel analyses of the genome. For example, quantitative gene expression data, coupled with clinical and pharmacological studies, potentially could lead to developing microarray assays for screening the effects of chemotherapeutic agents on gene expression. Also, the advent of SNP (Single Nucleotide Polymorphism) technology will identify individuals, through large scale genotyping that are susceptible to pharmacologic agents improving the efficacy of therapeutic modalities. This technology will enhance many research programs and provide unprecedented access to key elements of prognosis, diagnosis, gene discovery, and therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016056-26S1
Application #
6588806
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-05-01
Project End
2003-04-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Barger, Carter J; Zhang, Wa; Sharma, Ashok et al. (2018) Expression of the POTE gene family in human ovarian cancer. Sci Rep 8:17136
Chen, George L; Carpenter, Paul A; Broady, Raewyn et al. (2018) Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24:373-380
Eng, Kevin H; Szender, J Brian; Etter, John Lewis et al. (2018) Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet 14:e1007194
Tubbs, Anthony; Sridharan, Sriram; van Wietmarschen, Niek et al. (2018) Dual Roles of Poly(dA:dT) Tracts in Replication Initiation and Fork Collapse. Cell 174:1127-1142.e19
Bucsek, Mark J; Giridharan, Thejaswini; MacDonald, Cameron R et al. (2018) An overview of the role of sympathetic regulation of immune responses in infectious disease and autoimmunity. Int J Hyperthermia 34:135-143
Leonova, Katerina; Safina, Alfiya; Nesher, Elimelech et al. (2018) TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells. Elife 7:
Verma, Aparajita; Rich, Laurie J; Vincent-Chong, Vui King et al. (2018) Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer. J Oral Pathol Med 47:484-491
Sheffer, Christine E; Miller, Austin; Bickel, Warren K et al. (2018) The treasure of now and an uncertain future: Delay discounting and health behaviors among cancer survivors. Cancer 124:4711-4719
Nesher, Elimelech; Safina, Alfiya; Aljahdali, Ieman et al. (2018) Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Res 78:1431-1443
Azad, T; Janse van Rensburg, H J; Lightbody, E D et al. (2018) A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat Commun 9:1061

Showing the most recent 10 out of 1555 publications